Clinical Trial 22170

• Overview

  Study Title:

  Feasibility of Generating Novel Translational and Therapeutic Strategies based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)

  Summary:

  This Study will evaluate the ability of a multidisciplinary and multisite group, the Pediatric Evolutionary Tumor Board (pedsETB), to develop additional therapeutic strategies in patients without curative options or with suboptimal outcomes.

  Objective:

  1. Primary Objective To evaluate the ability of a multidisciplinary and multisite group, the Pediatric Evolutionary Tumor Board (pedsETB), to develop additional therapeutic strategies in patients without curative options or with suboptimal outcomes.

• Treatments

  Therapies:

  Observational

  Medications:

  Not Applicable ()

• Inclusion Criteria

  Inclusion Criteria:
  • Patients must be considered likely incurable given the standard of care. This is inclusive of patients newly diagnosed, relapsed or in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but unlikely curative options for care. The site investigator will make this determination based on their experience.
  • Patient must have an age-appropriate performance status: Karnofsky of 50 or more for patients 16 years of age or older, or Lansky score of 50 or more for patients less than16 years of age.
  • Patient and/or parents or legal guardian and primary oncologist must be willing to consider the therapeutic strategies recommended by the pedsETB.
  • Patient must be willing to be followed over time and allow collection of clinical data including scans, available blood and lab samples, and optional pedsETB serial blood sampling.
  • All patients and/or their parents or legal guardians must have the ability to understand and the willingness to sign a written informed consent or assent document.

• Exclusion Criteria

  Exclusion Criteria:
  • Patients without known therapies to reliably induce a response are excluded from pedsETB and should seek clinical trials.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.